I agree that this site is using cookies. You can find further informations here.
X
Sohn, Joohyuk
86  results:
OpenAccess-fulltext X
Search for persons X
?
1

A Phase II Trial of S-1 and Oxaliplatin in Patients with Me..:

Lee, Dae-Won ; Keam, Bhumsuk ; Lee, Keun Seok...
Cancer Research and Treatment, Vol.55 No.2, pp.523-530.  , 2023
Link: https://hdl.handle.net/1..
 
?
2

Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxe..:

Lambertini, Matteo ; Ceppi, Marcello ; Anderson, Richard A...
https://dipot.ulb.ac.be/dspace/bitstream/2013/356790/3/Lambertini2023-JNCCN.pdf.  , 2023
Link: http://hdl.handle.net/20..
 
?
3

TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in..:

Bardia, Aditya ; Jhaveri, Komal ; Kalinsky, Kevin...
Future Oncology.  , 2023
Link: https://hdl.handle.net/1..
 
?
4

Clinical activity of nivolumab in combination with eribulin..:

Kim, Se Hyun ; Im, Seock-Ah ; Suh, Koung Jin...
European Journal of Cancer, Vol.195, p. 113386.  , 2023
Link: https://hdl.handle.net/1..
 
?
5

Targeting PEG10 as a novel therapeutic approach to overcome..:

Katuwal, Nar Bahadur ; Kang, Min Sil ; Ghosh, Mithun...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683152/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
6

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advan..:

Modi, Shanu ; Jacot, William ; Yamashita, Toshinari...
New England Journal of Medicine, Vol.387 No.1, pp.9-20.  , 2022
Link: https://hdl.handle.net/1..
 
?
7

Updated Overall Survival of Ribociclib plus Endocrine Thera..:

Lu, Yen-Shen ; Im, Seock-Ah ; Colleoni, Marco...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377723/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
8

Blood Test for Breast Cancer Screening through the Detectio..:

Park, Sunyoung ; Ahn, Sungwoo ; Kim, Jee Ye...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409068/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
9

Updated Overall Survival of Ribociclib plus Endocrine Thera..:

Lu, Yen-Shen ; Im, Seock-Ah ; Colleoni, Marco...
Clinical Cancer Research, Vol.28 No.5, pp.851-859.  , 2022
Link: https://hdl.handle.net/1..
 
?
10

Anaemia and pathologic complete response rate according to ..:

Ji, Jung Hwan ; Bae, Soong June ; Kim, Seul‐Gi...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883435/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advan..:

Modi, Shaun ; Jacot, William ; Yamashita, Toshinari...
Reproducció del document publicat a: https://doi.org/10.1056/nejmoa2203690.  , 2022
Link: http://hdl.handle.net/24..
 
?
12

Abemaciclib plus fulvestrant in East Asian women with HR+, ..:

Toi, Masakazu ; Huang, Chiun‐Sheng ; Im, Young‐Hyuck...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807498/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
13

Clinical Significance of PIK3CA and ESR1 Mutations in Circu..:

Tolaney, Sara M ; Toi, Masakazu ; Neven, Patrick...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234145/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
14

Talazoparib versus Chemotherapy in Patients with HER2-Negat..:

Lee, Kyung-Hun ; Sohn, Joohyuk ; Goodwin, Annabel...
Cancer Research and Treatment, Vol.53 No.4, pp.1084-1095.  , 2022
Link: https://hdl.handle.net/1..
 
?
15

Phase II study to investigate the efficacy of trastuzumab b..:

Sim, Sung Hoon ; Kim, Jeong Eun ; Kim, Min Hwan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429798/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
1-15